Begins rolling FDA NDA for QTORIN 3.9% rapamycin gel in microcystic lymphatic malformations
Completion of the NDA remains targeted for H2 2026 under FDA rolling review, supported by Breakthrough Therapy and Fast Track designations. - Preparing for potential US launch in H1 2027, pending FDA clearance.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.